Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 16/20 | 0.85 |
| ▸ | CA12 | O43570 | 15/20 | 0.85 |
| ▸ | CA2 | P00918 | 6/20 | 0.85 |
| ▸ | RAB9A | P51151 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.85 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.85 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.85 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.85 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.85 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.85 |
| ▸ | CA1 | P00915 | 11/20 | 0.67 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.60 |
| ▸ | BMP1 | P13497 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Probenecid SCHEMBL1034640 | 0.92 | CA9 (1.00) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL3663 | 0.92 | CA9 (1.00) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636804 | 0.91 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636803 | 0.91 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL22325443 | 0.91 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL23630240 | 0.91 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636778 | 0.91 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL23391020 | 0.91 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636781 | 0.91 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL28892826 | 0.91 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4132503-B1 | PROBENECID FOR USE IN THE TREATMENT OF SARS-CO-V2 INFECTIONS | UNIV GEORGIA (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4132503-B1 | PROBENECID FOR USE IN THE TREATMENT OF SARS-CO-V2 INFECTIONS | UNIV GEORGIA (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20240285561-A1 | METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11903916-B2 | Methods of using probenecid for treatment of coronavirus infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| CN-116075298-A | Methods for treating coronavirus infection | 佐治亚大学研究基金会股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4132503-A1 | METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS | University of Georgia Research Foundation, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3892269-B1 | PROBENECID FOR TREATING CORONAVIRUS INFECTIONS | UNIV GEORGIA (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20210393564-A1 | METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2021-12-23 | — | — | US | disclosed |
| EP-3892269-A1 | PROBENECID FOR TREATING CORONAVIRUS INFECTIONS | University of Georgia Research Foundation, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-11116737-B1 | Methods of using probenecid for treatment of coronavirus infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2021-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903916-B2 | Methods of using probenecid for treatment of coronavirus infections | ACE2, ACE, SARS1 | CA9 217/4885CA12 144/4885CA2 170/4885 |
| US-11116737-B1 | Methods of using probenecid for treatment of coronavirus infections | ACE2, ACE, SARS1 | CA9 217/4885CA12 144/4885CA2 170/4885 |
| US-20240285561-A1 | METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS | ACE2, ACE, TMPRSS2 | CA9 218/4885CA12 86/4885CA2 136/4885 |
| US-20210393564-A1 | METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | CA9 217/4885CA12 144/4885CA2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.